Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 16/20 | 0.50 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.47 |
| ▸ | CDK1 | P06493 | 1/20 | 0.47 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.47 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.47 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.46 |
| ▸ | CDK2 | P24941 | 1/20 | 0.46 |
| ▸ | DAO | P14920 | 1/20 | 0.45 |
| ▸ | CLK2 | P49760 | 2/20 | 0.43 |
| ▸ | CLK3 | P49761 | 2/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3672721 | 0.77 | RIPK1 (0.54) | RIPK1CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL5669939 | 0.74 | RAB9A (0.48) | — | |
| SCHEMBL31374627 | 0.73 | RIPK1 (0.58) | RIPK1CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL14838870 | 0.72 | CCNB2 (0.65) | RIPK1CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL31704117 | 0.72 | CCNB2 (0.65) | RIPK1CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL1780991 | 0.71 | CYP19A1 (0.66) | RIPK1CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL1538594 | 0.71 | DAO (0.46) | RIPK1CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL2595303 | 0.71 | DAO (0.53) | RIPK1CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL1778505 | 0.70 | RIPK1 (0.74) | RIPK1CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL20670460 | 0.70 | RIPK1 (0.54) | RIPK1CCNB2CDK1CCNB1CCNB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 232 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10071156-B2 | Aqueous gel formulations containing immune response modifiers | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2018-09-11 | — | — | US | claimed |
| US-20160101173-A1 | AQUEOUS GEL FORMULATIONS CONTAINING IMMUNE RESPONSE MODIFIERS | 3M INNOVATIVE PROPERTIES CO (US) | 2016-04-14 | — | — | US | claimed |
| US-9248127-B2 | Aqueous gel formulations containing immune response modifiers | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2016-02-02 | — | — | US | claimed |
| US-20090163532-A1 | Aqueous Gel Formulations Containing Immune Response Modifiers | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2009-06-25 | — | — | US | claimed |
| EP-1844201-A2 | AQUEOUS GEL FORMULATIONS CONTAINING IMMUNE RESPONSE MODIFIERS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2007-10-17 | — | — | EP | claimed |
| WO-2006084251-A2 | AQUEOUS GEL FORMULATIONS CONTAINING IMMUNE REPONSE MODIFIERS | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2006-08-10 | — | — | WO | claimed |
| EP-0526840-B1 | Condensed naphthyridine derivatives | KYOWA HAKKO KOGYO KK (JP) | 1997-10-22 | — | — | EP | claimed |
| US-5281610-A | Pyrazolonaphthyridine pharmaceuticals | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1994-01-25 | — | — | US | claimed |
| EP-0526840-A1 | Condensed naphthyridine derivatives | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1993-02-10 | — | — | EP | claimed |
| US-20240173390-A1 | PEPTIDE VACCINE FORMULATIONS AND USE THEREOF FOR INDUCING AN IMMUNE RESPONSE | THE U.S.A, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2024-05-30 | — | — | US | disclosed |
| WO-2024092028-A2 | COMBINATION TREATMENT REGIMES FOR TREATING CANCER | VACCITECH NORTH AMERICA, INC. (US) | 2024-05-02 | — | — | WO | disclosed |
| WO-2024092030-A1 | SELF-ASSEMBLING NANOPARTICLES | VACCITECH NORTH AMERICA, INC. (US) | 2024-05-02 | — | — | WO | disclosed |
| US-11938177-B2 | Peptide vaccine formulations and use thereof for inducing an immune response | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2024-03-26 | — | — | US | disclosed |
| EP-4294431-A1 | SELF-ASSEMBLING NANOPARTICLES BASED ON AMPHIPHILIC PEPTIDES | Vaccitech North America, Inc. (US) | 2023-12-27 | — | — | EP | disclosed |
| WO-2005079195-A2 | PYRAZOLOPYRIDINES AND ANALOGS THEREOF | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2005-09-01 | — | — | WO | disclosed |
| EP-0526840-B1 | Condensed naphthyridine derivatives | KYOWA HAKKO KOGYO KK (JP) | 1997-10-22 | — | — | EP | disclosed |
| US-5281610-A | Pyrazolonaphthyridine pharmaceuticals | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1994-01-25 | — | — | US | disclosed |
| US-5281610-A | Pyrazolonaphthyridine pharmaceuticals | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1994-01-25 | — | — | US | disclosed |
| EP-0526840-A1 | Condensed naphthyridine derivatives | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1993-02-10 | — | — | EP | disclosed |
| EP-0526840-A1 | Condensed naphthyridine derivatives | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1993-02-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240173390-A1 | PEPTIDE VACCINE FORMULATIONS AND USE THEREOF FOR INDUCING AN IMMUNE RESPONSE | NGLY1, MYD88, SPPL2B | RIPK1 1275/4885CCNB2 2387/4885CDK1 4054/4885 |
| US-10071156-B2 | Aqueous gel formulations containing immune response modifiers | IFNG, ICOS, IL4 | RIPK1 1412/4885CCNB2 1438/4885CDK1 562/4885 |
| US-11938177-B2 | Peptide vaccine formulations and use thereof for inducing an immune response | NGLY1, MYD88, SPPL2B | RIPK1 1275/4885CCNB2 2387/4885CDK1 4054/4885 |
| US-20090163532-A1 | Aqueous Gel Formulations Containing Immune Response Modifiers | IFNG, ICOS, IL4 | RIPK1 1412/4885CCNB2 1438/4885CDK1 562/4885 |
| US-20160101173-A1 | AQUEOUS GEL FORMULATIONS CONTAINING IMMUNE RESPONSE MODIFIERS | IFNG, ICOS, IL4 | RIPK1 1412/4885CCNB2 1438/4885CDK1 562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.